Literature DB >> 32826171

Real-world dosimetric comparison between CyberKnife SBRT and HDR brachytherapy for the treatment of prostate cancer.

Georgios Chatzikonstantinou1, Christian Keller2, Christian Scherf3, Bastian Bathen2, Janett Köhn2, Nikolaos Tselis3.   

Abstract

PURPOSE: High-dose-rate (HDR) brachytherapy (BRT) and stereotactic body radiotherapy (SBRT) are currently the two treatment options for definitive radiotherapy of prostate cancer, employing extreme hypofractionation. There are only very few studies comparing their dosimetry, all using computed tomography for treatment planning. We present here a real-word dosimetric comparison between SBRT and ultrasound-based virtual HDR-BRT, with both imaging modalities coming from the same patient. METHODS AND MATERIALS: Patients with prostate cancer on a prospective trial evaluating the toxicity of robotic-based SBRT were treated to a total dose of 35 Gy in 5 fractions. Fifteen patients were included in this analysis. During ultrasound-based fiducial implantation, a three-dimensional data set as in real HDR-BRT procedure was acquired. Virtual HDR-BRT plans were generated and various organs at risk and prostate dosimetric parameters were evaluated.
RESULTS: Concerning prostate, SBRT achieved significant higher D98, V35 Gy, and V37.5 Gy coverage, whereas virtual HDR-BRT achieved significant higher intratumoral doses reflected in the V42 Gy and V52.5 Gy. Rectal Dmax, V36 Gy, and V29 Gy were significantly lower for HDR-BRT with no difference as for V18 Gy. SBRT was significantly inferior regarding bladder dosimetry (Dmax, V36 Gy, V18 Gy), whereas urethra Dmax and V44 Gy where significantly higher at the expense of HDR-BRT.
CONCLUSIONS: HDR-BRT is superior regarding rectum and bladder dosimetry, with SBRT being superior relative to urethra dosimetry. A randomized study is warranted to define the best extreme hypofractionated modality.
Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dosimetric comparison; Extreme hypofractionation; HDR-BRT; Prostate cancer; SBRT

Year:  2020        PMID: 32826171     DOI: 10.1016/j.brachy.2020.07.011

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

Review 1.  Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer.

Authors:  Manon Kissel; Gilles Créhange; Pierre Graff
Journal:  Cancers (Basel)       Date:  2022-04-29       Impact factor: 6.575

2.  A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer.

Authors:  Sergey Nikolaevich Novikov; Roman Vladimirovich Novikov; Yurii Olegovich Merezhko; Mariya Yurevna Gotovchikova; Nikolai Dmitrievich Ilin; Yulia Sergeevna Melnik; Sergey Vasilevich Kanaev
Journal:  Radiat Oncol J       Date:  2022-09-30

Review 3.  The value of brachytherapy in the age of advanced external beam radiotherapy: a review of the literature in terms of dosimetry.

Authors:  Tibor Major; Georgina Fröhlich; Péter Ágoston; Csaba Polgár; Zoltán Takácsi-Nagy
Journal:  Strahlenther Onkol       Date:  2021-11-01       Impact factor: 3.621

4.  Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.

Authors:  Hideya Yamazaki; Koji Masui; Gen Suzuki; Norihiro Aibe; Daisuke Shimizu; Takuya Kimoto; Kei Yamada; Akihisa Ueno; Toru Matsugasumi; Yasuhiro Yamada; Takumi Shiraishi; Atsuko Fujihara; Ken Yoshida; Satoaki Nakamura
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.